KOMZIFTI Revenue Jumps 53% to $13.9M as Kura Lands FDA Alignment on Second Program
KURA is trading near its 52-week low of $6.75 (10% above the low).
Summary
KOMZIFTI net product revenue hit $13.9 million in Q3 2026, up 53% from Q2's $9.1 million, with new patient starts up 30% and total prescriptions up 65%. Kura kept majority share of new patient starts in the R/R NPM1-mutant AML menin inhibitor market, so the launch is taking share rather than just riding class growth. The company also reached FDA alignment on a roughly 40-patient single-arm registrational study of darlifarnib in HRAS-mutant salivary gland cancer, with initiation targeted for 1H 2027 — a potential second approval path. Cash and short-term investments stood at $492.1 million at September 30, down from $667.2 million at year-end 2025, and management says resources plus anticipated Kyowa Kirin milestone payments and up to $300 million of Oberland Capital capacity fund operations beyond the KOMET-017 frontline topline in 2028. Net loss narrowed to $70.2 million from $74.1 million a year ago. Kura now guides 2026 collaboration revenue to $40 million to $45 million, while keeping $90 million to $110 million for each of 2027 and 2028. Watch the ASH 2026 presentations, including two oral sessions on ziftomenib plus FLT3 inhibitor combinations, for the next read on the frontline AML expansion.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Kura updated 2026 collaboration revenue guidance to $40 million to $45 million, maintaining $90 million to $110 million for each of 2027 and 2028.
At the time of this announcement, KURA was trading at $7.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $673.4M. The 52-week trading range was $6.75 to $13.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.